StreetInsider.com News Articles

Form 424B5 Oruka Therapeutics, Inc.

Fri, 28 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260828/26997982.html

Form 424B5 Oruka Therapeutics, Inc.

Fri, 28 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260828/26997982.html

Form EFFECT Oruka Therapeutics, Inc.

Fri, 28 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260828/26992640.html

Form EFFECT Oruka Therapeutics, Inc.

Fri, 28 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260828/26992640.html

Form 4 Oruka Therapeutics, Inc. For: Aug 24 Filed by: Edwards Larry Todd

Tue, 25 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260825/26975071.html

Form 4 Oruka Therapeutics, Inc. For: Aug 24 Filed by: Edwards Larry Todd

Tue, 25 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260825/26975071.html

Form 3 Oruka Therapeutics, Inc. For: Aug 24 Filed by: Edwards Larry Todd

Tue, 25 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260825/26974778.html

Form 3 Oruka Therapeutics, Inc. For: Aug 24 Filed by: Edwards Larry Todd

Tue, 25 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260825/26974778.html

Form 8-K Oruka Therapeutics, Inc. For: Aug 24

Mon, 24 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260824/26968127.html

Form 8-K Oruka Therapeutics, Inc. For: Aug 24

Mon, 24 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260824/26968127.html

Oruka Therapeutics names Todd Edwards as chief commercial officer

Mon, 24 Aug 2026 16:01:14 -0400

Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biotechnology company focused on chronic skin diseases, announced the appointment of Todd Edwards as Chief Commercial Officer, effective Aug. 24, 2026.

Edwards joins Oruka from Arcutis Biotherapeutics, where he served as Executive Vice President and Chief Commercial Officer. In that role, he led the rebuild of the ZORYVE franchise, launched new indications in atopic dermatitis and seborrheic dermatitis, and oversaw revenue growth.

Before Arcutis, Edwards held the position of Group Vice President and Business Head of Immunology at Incyte Corporation, where he established a dermatology business unit and launched two dermatology therapies. He also held

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Mon, 24 Aug 2026 16:01:00 -0400

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026.

Mr. Edwards brings more than 25 years of commercial leadership experience across immunology and dermatology, spanning both biologics and topical therapies. He joins Oruka from Arcutis Biotherapeutics, Inc., where he served as Executive Vice President and Chief Commercial Officer

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Mon, 24 Aug 2026 16:01:00 -0400

Oruka Therapeutics (ORKA) files $1B mixed shelf

Fri, 21 Aug 2026 16:20:56 -0400

Oruka Therapeutics (NASDAQ: ORKA) filed $1,000,000,000 mixed shelf of:

Common Stock

Preferred Stock

Depositary Shares

Warrants

Oruka Therapeutics (ORKA) files $1B mixed shelf

Fri, 21 Aug 2026 16:20:56 -0400

Oruka Therapeutics (NASDAQ: ORKA) filed $1,000,000,000 mixed shelf of:

Common Stock

Preferred Stock

Depositary Shares

Warrants

Form S-3 Oruka Therapeutics, Inc.

Fri, 21 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260821/26961650.html

Form S-3 Oruka Therapeutics, Inc.

Fri, 21 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260821/26961650.html

Form 4 Oruka Therapeutics, Inc. For: Aug 17 Filed by: Goncalves Joana

Mon, 17 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26939143.html

Form 4 Oruka Therapeutics, Inc. For: Aug 17 Filed by: Goncalves Joana

Mon, 17 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26939143.html

Form 4 Oruka Therapeutics, Inc. For: Aug 14 Filed by: Quinlan Paul T

Fri, 14 Aug 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26933048.html

Form 4 Oruka Therapeutics, Inc. For: Aug 14 Filed by: Quinlan Paul T

Fri, 14 Aug 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26933048.html

Form 4 Oruka Therapeutics, Inc. For: Aug 13 Filed by: Agarwal Arjun

Fri, 14 Aug 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260814/26933012.html

Form 4 Oruka Therapeutics, Inc. For: Aug 13 Filed by: Agarwal Arjun

Fri, 14 Aug 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260814/26933012.html

Form SCHEDULE 13G/A Oruka Therapeutics, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260814/26932313.html

Form SCHEDULE 13G/A Oruka Therapeutics, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260814/26932313.html